Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Preclinical discovery and development of colesevelam for the treatment of type 2 diabetes

Research output: Contribution to journalJournal articleResearchpeer-review

  1. The design and discovery of lixisenatide for the treatment of type 2 diabetes mellitus

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Status of drug development for the prevention and treatment of osteoporosis

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. The Liver-α-Cell Axis and Type 2 Diabetes

    Research output: Contribution to journalReviewResearchpeer-review

  2. Endogenous glucose-dependent insulinotropic polypeptide exerts diverging and tissue specific in obese patients with type 2 diabetes

    Research output: Contribution to journalConference abstract in journalResearchpeer-review

  3. Gut-derived glucagon in man

    Research output: Contribution to journalConference abstract in journalResearchpeer-review

  4. The glucagon-like peptide-1 receptor agonist, liraglutide, does not suppress postprandial cholecystokinin in patients with type 1 diabetes

    Research output: Contribution to journalConference abstract in journalResearchpeer-review

  5. The role of glucagon-like peptide 1 for the postprandial effects of metformin in type 2 diabetes

    Research output: Contribution to journalConference abstract in journalResearchpeer-review

View graph of relations

INTRODUCTION: Type 2 diabetes (T2D) is a major global health challenge associated with increased cardiovascular morbidity and mortality. Intervention strategies managing multiple risk factors (hyperglycemia, hypertension and dyslipidemia) in patients with T2D can reduce the risk of cardiovascular disease by ~50%. Areas covered: Herein, the authors provide an update on the development and clinical potential of colesevelam as a glucose-lowering drug in T2D. Furthermore, they outline the pharmacokinetics, pharmacodynamics and the clinical efficacy and safety data from the studies carried out to obtain market authorization for colesevelam. Expert opinion: Four phase III clinical trials provide evidence that colesevelam, as a monotherapy and add-on to various background glucose-lowering treatments, confers placebo-corrected reductions in HbA1c of ~5 mmol/mol. In addition, colesevelam reduces low-density lipoprotein (LDL) cholesterol and total cholesterol. Some antidiabetic agents seem superior to colesevelam in terms of clinical efficiency (HbA1c lowering), tolerability/convenience and price. Nonetheless, colesevelam offers a clinically relevant combination of HbA1c- and LDL-lowering that in selected patients could be relevant as add-on treatment to other glucose-lowering drugs and a statin. Potential patients include those with renal impairment, and patients that are close to reaching their lipid and glycemic treatment goals but need further LDL and HbA1c reductions.

Original languageEnglish
JournalExpert Opinion on Drug Discovery
Volume13
Issue number12
Pages (from-to)1161-1167
Number of pages8
ISSN1746-0441
DOIs
Publication statusPublished - Oct 2018

ID: 55494362